#INAB

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager IN8bio (Nasdaq: INAB) announced a private placement priced at-the-market to raise up to $40.2 million, with an initial closing of approximately $20.1 million expected around Dec 22, 2025. The initial tranche sells 5,127,029 shares at $1.38 and pre-funded warrants for up to 9,452,677 shares (exercise price $0.0001). The company may receive an additional $20.1 million subject to preclinical milestones and share-price conditions. Net proceeds are intended to fund IND-enabling studies for INB-619, generate early animal data in 2026, support potential IND submission in 2027, submit INB-200/INB-400 glioblastoma data to the FDA, and provide working capital into the first half of 2027.

2 months ago

#INAB IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

www.stocktitan.net/news/INAB/in8bio-announc...

0 0 0 0

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrating equivalent potency comparable to FDA-approved commercial products with minimal adverse cytokine release, highlighting its potential to achieve deep B cell depletion with an improved safety

4 months ago

#INAB IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/INAB/in8bio-reports...

0 0 0 0

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site IN8bio (Nasdaq: INAB) announced that The Ohio State University has been added as a new clinical site in the ongoing Phase 1 trial of INB-100, a donor-derived allogeneic gamma-delta T cell therapy for patients receiving haploidentical stem cell transplants for leukemia.The company said the addition aims to accelerate enrollment of the expansion cohort and deliver follow-up data next year. IN8bio noted clinical observations including long-term leukemic remissions beyond four and five years in earliest-treated patients, persistence and expansion of INB-100 up to 1 year, and an absence of severe graft-versus-host disease in presented data. Trial identifier: NCT03533816.

4 months ago

#INAB IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

www.stocktitan.net/news/INAB/in8bio-expands...

0 0 0 0

IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications IN8bio (Nasdaq: INAB) on Oct. 27, 2025 presented preclinical data for INB-619, a pan-γδ T cell engager targeting CD19 for autoimmune disease. In SLE donor models INB-619 achieved complete B cell elimination with efficacy described as equivalent to approved engagers blinatumomab and mosunetuzumab, while producing markedly lower IL-6 and other cytokines. INB-619 expanded both Vδ1+ and Vδ2+ γδ T cell subsets and did not activate CD4+ or CD8+ αβ T cells in these assays. Data were presented at the 2025 ACR Convergence Meeting and are preclinical, indicating potential for deeper B cell depletion with a cytokine-sparing profile.

4 months ago

#INAB IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications

www.stocktitan.net/news/INAB/in8bio-present...

0 0 0 0

7 months ago

News; ( NASDAQ: #INAB ) Expected earnings - IN8bio Inc.

0 0 0 0

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights IN8bio (Nasdaq: INAB) reported significant clinical progress and financial results for Q2 2025. The company achieved a remarkable milestone in its INB-200 glioblastoma trial, with one patient surpassing four years without progression. Clinical data presented at ASCO 2025 showed patients receiving multiple doses achieved median progression-free survival of 16.1 months, more than double the standard-of-care outcome.The company received recognition for its DeltEx™ manufacturing platform and presented promising preclinical data for INB-619, a gamma-delta T cell engager showing potential in lupus treatment. Financial results showed R&D expenses of $2.5M and G&A expenses of $2.7M, with a cash position of $13.2M extending runway into June 2026.

7 months ago

#INAB IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/INAB/in8bio-reports...

0 0 0 0

Revolutionary Cancer Treatment Keeps Glioblastoma Patient in Remission for 4 Years - Double Standard Survival Rate Groundbreaking gamma-delta T cell therapy shows unprecedented 4-year remission in glioblastoma trial, doubling standard survival rates. See full patient outcomes.

9 months ago

#INAB IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

www.stocktitan.net/news/INAB/in8bio-recogni...

0 0 0 0

Breakthrough Brain Cancer Treatment Doubles Survival Time: IN8bio's Phase 1 Trial Reveals Groundbreaking Results New gamma-delta T cell therapy extends GBM survival to 16.1 months, with 40% of patients alive past 2 years. Learn how this breakthrough changes brain cancer treatment.

9 months ago

#INAB IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

www.stocktitan.net/news/INAB/in8bio-present...

0 0 0 0

Breakthrough in Lupus Treatment: IN8bio's New Therapy Achieves Complete B Cell Depletion Without Dangerous Side Effects New data reveals safer approach to lupus treatment using gamma-delta T cells. Complete B cell elimination achieved without cytokine release syndrome risk. See full results.

10 months ago

#INAB IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025

www.stocktitan.net/news/INAB/in8bio-present...

0 0 0 0

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products IN8bio (NASDAQ: INAB) presented new data on its proprietary gamma-delta (γδ) T cell manufacturing program at ISCT 2025, receiving the Host Region Abstract Award. The company's DeltEx™ Allo manufacturing process demonstrated consistent production of potent cellular therapies for cancer treatment.Key findings from the INB-100 study revealed: (1) Successful TCR reprogramming from αβ to γδ across all clinical batches, (2) High expression of cancer-killing and immune activation genes, and (3) Remarkable clinical outcomes with all 10 initial cohort patients remaining relapse-free for over a year, achieving a median overall survival of 23.3 months as of January 2024.The company has automated its manufacturing program for rapid, reproducible production of cryopreserved cell therapy doses. The INB-100 trial is currently enrolling an expansion cohort at the recommended Phase 2 dose.

10 months ago

#INAB IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products

www.stocktitan.net/news/INAB/in8bio-present...

0 0 0 0

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free with median follow-up of 20.1 months as of January 17, 2025, as presented at the 2025 Transplantation & Cellular Therapy (TCT)

10 months ago

#INAB IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/INAB/in8bio-reports...

0 0 0 0

Breakthrough Cancer Treatment Platform Eliminates Deadly Side Effects: New Data Reveals Dual-Target Success New gamma-delta T cell platform demonstrates potent anti-cancer activity at picomolar levels while avoiding cytokine storms. See complete efficacy data.

10 months ago

#INAB IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025

www.stocktitan.net/news/INAB/in8bio-unveils...

0 0 0 0

Zacks Small Cap Research

@zackssmallcap.bsky.social

11 months ago

#INAB: Introducing INB-600, A γδ T Cell Engager Platform buff.ly/75v3r2f

0 0 0 0

IN8bio's Breakthrough: Perfect Response Rate in AML Treatment While Managing Financial Challenges IN8bio achieves 100% durable response in AML patients with INB-100 therapy, while extending cash runway to 2026. Key advances in glioblastoma treatment show 40-month survival benefit.

1 year ago

#INAB IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

www.stocktitan.net/news/INAB/in8bio-reports...

0 0 0 0

Can IN8bio's New Gamma-Delta Platform Solve CAR-T's Biggest Safety Problems? Novel TCE platform shows rapid B-cell depletion with reduced cytokine release, potentially offering safer alternatives for blood cancers and autoimmune conditions.

1 year ago

#INAB IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

www.stocktitan.net/news/INAB/in8bio-announc...

0 0 0 0

Zacks Small Cap Research

@zackssmallcap.bsky.social

1 year ago

#INAB: Continued Survival in INB-100 Trial buff.ly/4i1bbnu

0 0 0 0

Revolutionary AML Treatment Data: Complete Remission in All Patients After 20 Months Groundbreaking Phase 1 results show 90.9% progression-free survival and 100% overall survival in high-risk AML patients, with zero relapses after 20.1 months.

1 year ago

#INAB IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

www.stocktitan.net/news/INAB/in8bio-present...

0 0 0 0

1 year ago

BREAKING NEWS: ( NASDAQ: #INAB ) IN8bio Reports Promising Phase 1 Trial of INB-100 in Leukemia Patients Data

0 0 0 0

Breakthrough AML Treatment: IN8bio's Cell Therapy Achieves Perfect Remission Rate in Phase 1 Groundbreaking results show 100% survival rate and complete remission in AML patients using INB-100 therapy, with some patients cancer-free for 3+ years.

1 year ago

#INAB IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

www.stocktitan.net/news/INAB/in8bio-reports...

0 0 0 0

1 year ago

Just In: ( NASDAQ: #INAB ) IN8bio to Present at Biotech Showcase 2025 in San Francisco

0 0 0 0

1 year ago

BREAKING NEWS: ( NASDAQ: #INAB ) IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

#StockMarket #News

0 0 0 0

1 year ago

#INAB IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting

www.stocktitan.net/news/INAB/in8bio-reports...

0 0 0 0